Cold tumors are malignancies with insufficient spontaneous T-cell and natural killer (NK) cell infiltration and activation, resulting in poor responses to immune checkpoint blockade. A mechanistic framework increasingly implicates stress-responsive tumor microenvironments that actively reprogram cytotoxic lymphocytes. Central to this concept is the growth differentiation factor 15 (GDF15) signaling pathway and its interaction with xenobiotic-sensing machinery, described as the GDF15–”xenobiotic receptor” axis. While the specific xenobiotic receptor may vary by experimental context, the overarching biology is consistent: tumor-associated stress signals engage receptors that typically regulate detoxification and xenobiotic metabolism, repurposing these pathways to alter immune cell fate. This creates immunologically “cold” conditions characterized by NK cell dysfunction, impaired cytotoxicity, and reduced cytokine production.
GDF15 is a stress-inducible cytokine-like molecule produced by many cell types, including stressed epithelial and stromal compartments. In cancer, GDF15 can be induced by hypoxia, mitochondrial dysfunction, oxidative stress, inflammatory signaling, and nutrient deprivation. Once secreted, GDF15 can act in autocrine and paracrine fashions, shaping the tumor microenvironment (TME). The TME is not merely a passive niche; it is a biochemical and mechanical system that governs immune trafficking, activation thresholds, and metabolic fitness. Persistent stress cues elevate GDF15 concentrations, which then condition nearby immune cells through receptor-mediated signal transduction.
At the receptor level, xenobiotic-sensing pathways are evolutionarily designed to adjust gene expression programs in response to harmful chemical exposures. Tumors exploit this regulatory logic by stimulating immune cells to activate a similar transcriptional state. In NK cells, such reprogramming can manifest as maladaptation—NK cells remain present but fail to behave as effective effectors. Mechanistically, activation of stress-linked transcriptional programs may alter the expression of cytotoxic mediators (e.g., perforin/granzyme-related signatures), reduce responsiveness to activating cytokines such as interleukin-15 (IL-15) and type I interferons, and impair signaling downstream of activating receptors (including activating NK receptors and co-stimulatory pathways). The net outcome is reduced target recognition, attenuated degranulation, and a lowered interferon-gamma (IFN-γ) output.
NK cell maladaptation is also tightly coupled to metabolism. Immune effector function requires coordinated bioenergetics and redox balance. Stress-driven signals can steer NK cells toward metabolic states that favor survival over cytotoxic activity, including increased reliance on pathways that support endurance in hostile conditions (hypoxia, lactate accumulation, and altered lipid availability) at the cost of killing efficiency. By reprogramming transcription, the GDF15–xenobiotic receptor axis can indirectly promote an immunosuppressive milieu by influencing chemokines, adhesion molecules, and the production of additional suppressive factors from tumor cells and associated myeloid populations.
This biology is particularly relevant to cold tumors, where conventional immunotherapies have limited efficacy. Immune checkpoint inhibitors rely on the presence of pre-existing antitumor immunity or the ability of therapy to amplify it. If NK cells are maladapted and fail to produce IFN-γ, they contribute less to antigen presentation, dendritic cell activation, and subsequent T-cell priming. Consequently, T-cell infiltration remains low and adaptive immune responses fail to scale. In this setting, the tumor behaves as an immune-excluded or immune-silenced system, producing resistance.
Targeted therapy strategies therefore aim to interrupt maladaptive signaling. In concept, blocking the GDF15–xenobiotic receptor axis could restore NK effector programs, improve cytotoxicity, and enhance cytokine output. Restored NK function may also reshape the TME by increasing chemokine production that supports recruitment of additional immune cells, improving cross-talk with dendritic cells, and boosting T-cell priming. Importantly, such interventions may synergize with checkpoint blockade: by increasing innate immune stimulation, they can convert a cold tumor phenotype toward a more inflamed “hot” state, which is more responsive to immunotherapy.
Therapeutic translation typically requires careful validation of pathway components: which receptor mediates the effect in NK cells, how signaling differs across tumor types, and whether blockade affects NK-cell development, proliferation, or long-term survival. Because GDF15 is involved in systemic stress responses, safety considerations include potential off-target impacts on appetite, energy balance, and inflammatory regulation. Biomarker-driven approaches—using circulating GDF15, TME expression profiles, and NK-cell functional assays—may help identify patients most likely to benefit.
In summary, cold tumors can be promoted by environmental and cellular stress that elevates GDF15 and activates a xenobiotic-sensing receptor program in NK cells. This drives maladaptation characterized by impaired cytotoxicity and reduced cytokine signaling, limiting immune amplification and enabling immune evasion. Targeting the GDF15–xenobiotic receptor axis offers a rational avenue to restore NK effector function and improve responses to cancer immunotherapy.
Source: @sigtrans_sttt
Signal Transduction and Targeted Therapy (STTT): How does environmental stress promote cold tumors? This study shows that the GDF15–#Xenobiotic receptor axis drives NK cell maladaptation, uncovering a potential target to improve #Cancer #Immunotherapy. #STTT #OpenAccess:. #breaking
— @sigtrans_sttt May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
